Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AM1944
- Development stage
- Preclinical
- Lead developer
- Moderna
- Modality
- Vaccines & Immunotherapeutics, Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Implant
01
Overview
AM1944 is a preclinical-stage mRNA-eluting biodegradable implant being developed by AMW GmbH as a next-generation gene therapy and vaccine technology platform. Utilizing AMW's proprietary controlled-release formulation technology, the implant is designed to provide sustained delivery of mRNA directly to target tissues, minimizing systemic exposure and reducing dosing frequency. Prototyping and plausibility studies have been concluded, with initial development focusing on applications in prostate cancer and breast cancer.
- Other names
- AM-1944AM1944AM 1944
Beyond the preview
Go deeper on AM1944.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AM1944.